Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer

NCT06226350 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT06226350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06226350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2021
Completion date
January 3, 2024
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer